Table 3.
KEGG pathways enriched by genes targeted by the four candidate miRNAs (cancer pathways are not included)
| miRNA(s) | KEGG pathway | Number of genes in pathway |
|||
|---|---|---|---|---|---|
| Total | Targeted | Expected numbers | P | ||
| All four miRNAs | Axon guidance | 127 | 57 | 29.3 | 1.0E-07* |
| miR-125b-5p, miR-365a-3p, and miR-770-5p | Rap1 signaling | 210 | 78 | 44 | 7.5E-08* |
| Focal adhesion | 206 | 76 | 43.2 | 1.6E-07* | |
| Thyroid hormone signaling | 114 | 46 | 23.9 | 4.20E-06 | |
| MAPK signaling | 255 | 83 | 53.4 | 1.30E-05 | |
| Cholinergic synapse | 111 | 41 | 23.3 | 1.60E-04 | |
| miR-125b-5p, miR-365a-3p, and miR-5190 | Neurotrophin signaling | 120 | 49 | 22.8 | 6.3E-08* |
| cGMP-PKG signaling | 166 | 56 | 31.6 | 8.70E-06 | |
| miR-365a-3p, miR-770-5p, and miR-5190 | Oxytocin signaling | 158 | 43 | 22.9 | 4.20E-05 |
| miR-125b-5p and miR-365a-3p | ErbB signaling | 87 | 34 | 14.3 | 1.10E-06 |
| Sphingolipid signaling | 120 | 42 | 19.8 | 1.40E-06 | |
| Insulin resistance | 108 | 38 | 17.8 | 4.30E-06 | |
| Ras signaling | 226 | 64 | 37.3 | 8.00E-06 | |
| Hepatitis B | 145 | 46 | 23.9 | 8.40E-06 | |
| Insulin signaling | 138 | 44 | 22.7 | 1.20E-05 | |
| Wnt signaling | 138 | 44 | 22.7 | 1.20E-05 | |
| HIF-1 signaling | 98 | 34 | 16.2 | 2.10E-05 | |
| PI3K-Akt signaling | 345 | 84 | 56.9 | 1.30E-04 | |
| miR-125b-5p and miR-770-5p | Adherens junction | 71 | 29 | 12.7 | 1.50E-05 |
| miR-365a-3p and miR-770-5p | HTLV-I infection | 256 | 55 | 30.2 | 1.10E-05 |
HTLV-I, human T-cell leukemia virus type I.
*Pathways with strongest statistical support for enrichment with genes targeted by the four candidate miRNAs.